Catalent, bucking Lonza M&A reports, buys out Pharmatek in all-cash deal

Apparent Lonza target Catalent ($CTLT) has produced an about-face with its buyout of drug development and clinical manufacturing company Pharmatek for an undisclosed sum.

Back in April, rumors began to surface that the CDMO was in the crosshairs of the Swiss research manufacturing service provider Lonza, but today it has announced an all-cash deal to acquire San Diego’s Pharmatek Laboratories.

This acquisition will “add extensive early-phase drug development capabilities from discovery to clinic, bring spray drying into Catalent’s portfolio of drug formulation and delivery technologies, and expand Catalent’s capability for handling highly potent compounds,” the NJ-based company said in a statement.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

First launched 17 years’ ago, Pharmatek works on dosage form development and clinical-scale cGMP manufacturing of oral, injectable and topical product, as well as its own drug development platform.

“Catalent continues to expand its industry-leading drug development and delivery technologies to help its pharmaceutical partners to fully unlock the potential of their molecules and provide better treatments for patients,” said Barry Littlejohns, president of Catalent’s drug delivery solutions business.

“Combined with Catalent’s existing technologies and network, the addition of Pharmatek’s well-established scientific expertise and spray dry capabilities will create an unparalleled drug development platform, while the San Diego facility will expand our West Coast presence and provides additional access to the Asia-Pacific markets.”

Catalent said Pharmatek’s price tag “will not be disclosed as it is not material to Catalent’s financial results.”

Early this morning the market was not overly impressed, with Catalent’s shares down 1.7% by 10AM ET, with a market cap of $3 billion. 

Suggested Articles

Matching the right patients to the right trials is a key piece of the recruitment puzzle. In oncology, it can be life and death.

U.K.-based CRO Sygnature Discovery is buying up fellow native life science services provider XenoGesis in order to boost its preclinical offerings.

PRA Health is tapping Deep Lens and the Microsoft Azure platform in matchmaking cancer patients to the right trials to speed up recruitment.